<SEC-DOCUMENT>0001193125-16-694630.txt : 20160829
<SEC-HEADER>0001193125-16-694630.hdr.sgml : 20160829
<ACCEPTANCE-DATETIME>20160829070208
ACCESSION NUMBER:		0001193125-16-694630
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160829
FILED AS OF DATE:		20160829
DATE AS OF CHANGE:		20160829

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		161856167

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d245094d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>FORM 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of August, 2016 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novogen Limited </B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Lionel Mateo </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lionel Mateo </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 29 August 2016 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g245094tx_pg03a.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX:NRT</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NASDAQ:NVGN</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Ltd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Company)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABN 37 063 259 754</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital Structure</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary&nbsp;Shares&nbsp;on&nbsp;issue:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">429 M</P> <P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr John O&#146;Connor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Bryce Carmine</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deputy Chairman</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr James Garner</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Managing Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Ian Phillips MNZM</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Iain Ross</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Steven Coffey</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prof Peter Gunning</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MARKET RELEASE</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">29&nbsp;August 2016</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOVOGEN APPOINTS KEY MANAGEMENT PERSONNEL TO DRIVE</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TRANSITION TO A DEVELOPMENT-FOCUSED ORGANISATION</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Dr Gordon Hirsch appointed as Chief Medical Officer, with responsibility for
clinical development of Novogen&#146;s pipeline - formerly Vice President and Regional Medical Officer at Sanofi.</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Dr Peng Leong appointed as Chief Business Officer, with responsibility for
partnering and corporate strategy - formerly Global Head of Oncology Business Development at Merck Serono.</B><B></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>New appointments will support Novogen&#146;s evolution into a broad-based drug
development company with world-class capabilities across discovery, development, and partnering.</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sydney, 29 August 2016 &#150; Australian oncology-focused biotechnology company, Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced the appointment of two
internationally experienced pharmaceutical industry executives to its management team. The newly-created positions will support Novogen&#146;s strategy of emphasising clinical development and partnering, while maintaining its existing core strengths
in drug discovery.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Gordon Hirsch will join the company as Chief Medical Officer,
commencing in the fourth quarter, with primary responsibility for driving global clinical development of Novogen&#146;s pipeline of cancer therapies.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Dr Hirsch has spent almost twenty years in the pharmaceutical industry where he has worked with Pfizer Inc (NYSE: PFE), Eli Lilly and Company (NYSE: LLY),
Sanofi SA (NYSE: SNY), and The Takeda Pharmaceutical Company (TYO: 4502). His career has involved a broad range of global responsibilities, stretching from early development to commercialisation, and including appointments in Australia, Japan,
France, and the United States, and encompassing a portfolio of products with global sales in the billions of dollars. He holds a medical degree from the University of the Witwatersrand in South Africa, and an MBA from Henley Business College in the
UK. Dr&nbsp;Hirsch will be based in Sydney, Australia.</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g245094tx_pg04.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Peng Leong will join the company as Chief Business Officer, commencing in September. Dr Leong will be
primarily responsible for identifying and negotiating in-licensing and out-licensing opportunities for Novogen, and will take a central role in the ongoing development and execution of Novogen&#146;s corporate strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Leong has spent eighteen years in the pharmaceutical industry, beginning as a scientist, and followed by eight years in healthcare investment banking and
private equity, and eight years in business development. Dr&nbsp;Leong started his career at Chiron Corporation, a pioneering biotechnology company based in California that was subsequently acquired by Novartis International AG (NYSE: NVS). While
working in healthcare investment banking at CIBC World Markets and Piper Jaffray, he was involved in raising more than US$&nbsp;1.4 billion for over 20 biotechnology companies. In his various roles, including his most recent position at Merck Serono
(FWB: MRK), Dr&nbsp;Leong has had a leadership role in the acquisition or sale of over US$&nbsp;1 billion in pharmaceutical product rights. He holds a PhD in Biochemistry from the University of Toronto, Canada and an MBA from the University of
California, Berkeley. Dr&nbsp;Leong will be based in Cambridge, Massachusetts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to these senior management appointments, Novogen has bolstered
its operational capabilities by hiring David Cain, formerly of Aviragen Therapeutics Inc (NASDAQ: AVIR), previously known as Biota Pharmaceuticals. Mr&nbsp;Cain will join Novogen as Director of Chemistry, Manufacturing, and Controls (CMC) and will
commence work with the company in October. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr James Garner, CEO of Novogen, commented, &#147;as we highlighted at the Shareholder Meeting in March, a key
part of our strategy for Novogen this year has been to evolve from a scientific, discovery-focused company to a development organisation, focused on moving programs into and through human trials. As our development candidates transition successively
into clinical studies, strong medical and development capabilities will be essential to oversee the progression of our portfolio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, in order to
realise sustainable long-term shareholder value from our pipeline, we will be looking to actively engage with potential partners to explore licensing opportunities, which may include both out-licensing of our existing development candidates and
carefully-considered addition of complementary assets to our portfolio. To succeed in these ambitions, we will need access to a more commercially-focused set of skills and relationships, working alongside the strong scientific capabilities that
already exist in Novogen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is therefore a great pleasure to have Gordon, Peng, and David join the Novogen team. Their expertise and experience in their
respective fields will bring a greater breadth to the organisation, and we are very much looking forward to working with them.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[ENDS] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g245094tx_pg04.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g245094tx_pg04.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novogen Limited </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Limited (ASX: NRT; NASDAQ: NVGN) is an oncology-focused biotechnology company based in Sydney, Australia. Novogen has two proprietary drug discovery
platforms (superbenzopyrans and anti-tropomyosins) with the potential to yield first-in-class agents across a range of oncology indications. The three lead molecules Cantrixil, Anisina, and Trilexium are in preclinical development, with the most
advanced molecule, Cantrixil, slated to enter clinical trials in late 2016. For more information, please visit: <U>www.novogen.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Forward
Looking Statement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains &#147;forward-looking statements&#148; within the meaning of section 27A of the Securities Act of
1933 and section&nbsp;21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as &#147;expects,&#148; &#147;appear,&#148; &#147;intends,&#148; &#147;hopes,&#148;
&#147;anticipates,&#148; &#147;believes,&#148; &#147;could,&#148; &#147;should,&#148; &#147;would,&#148; &#147;may,&#148; &#147;target,&#148; &#147;evidences&#148; and &#147;estimates,&#148; and other similar expressions, but these words are not the
exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company&#146;s drug development program, including, but not limited to the initiation, progress and outcomes of clinical
trials of the Company&#146;s drug development program, including, but not limited to Cantrixil, Anisina, Trilexium, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited
to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company&#146;s drug components, including, but not limited to, Cantrixil, Anisina,
Trilexium, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company&#146;s drug compounds, including, but not limited to, Cantrixil, Anisina,
Trilexium, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company&#146;s intellectual property or trade secrets, including, but not limited to, the intellectual property relating to Cantrixil,
Anisina, Trilexium, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on <FONT STYLE="white-space:nowrap">Form&nbsp;20-F</FONT> and its reports on <FONT
STYLE="white-space:nowrap">Form&nbsp;6-K.</FONT> Such statements are based on management&#146;s current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to
in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g245094tx_pg04.jpg" ALT="LOGO">
 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g245094tx_pg03a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g245094tx_pg03a.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X00Q:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 U+C4M8S R,2 W.2XQ-30Y,3$L(#(P,3,O,3 O,CDM
M,3$Z-#<Z,38@(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z,$1!0S$X0C,Y14,S,3%%-3DP148Y,#(P.$4R
M0D%%1C4B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z,$1!0S$X0C(Y14,S
M,3%%-3DP148Y,#(P.$4R0D%%1C4B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B \>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#IA,&4Y8F9A-2TQ869A+31E8C8M861F8BTQ
M.&0V-S9F-V1F,F4B('-T4F5F.F1O8W5M96YT240](G5U:60Z.6)A8V4U-&(M
M-#4X92TT-6-D+6%C8F(M9#<Y839D93EB,#8T(B\^(#QD8SIC<F5A=&]R/B \
M<F1F.E-E<3X@/')D9CIL:3YR<C$V-#0X,SPO<F1F.FQI/B \+W)D9CI397$^
M(#PO9&,Z8W)E871O<CX@/&1C.G1I=&QE/B \<F1F.D%L=#X@/')D9CIL:2!X
M;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9" M(#$U,3(Q,%].
M;W9O9V5N7T%P<&]I;G1S7T1R7T=A<FYE<E]!<U]#14\N9&]C>#PO<F1F.FQI
M/B \+W)D9CI!;'0^(#PO9&,Z=&ET;&4^(#PO<F1F.D1E<V-R:7!T:6]N/B \
M+W)D9CI21$8^(#PO>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T
M2%!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @   @ " #A"
M24T$)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,     !_]L
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MXQ]!M^#O6+F4A)\E[J?2_0R^JQR7% * 4 H!0"@% 759/U-S\\O\EJ@):@%
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MJD'5.O D<0=.H\* N*@% 5'0?-\(H >D^<^_0%* 4 H!0"@% * 4 H!0"@%
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M(GXE^3E+TL\%>BTM#R3OU20>QL_!50RRSTGSFJ I0"@% * 4 H!0"@% * 4
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M#J>;#K3C9Z%H4G[X.A^_50RR'6UM.*0L:*2H@CS=?F(H$==4 H!0"@% * 4
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M\Y+R?YLP\/!O9-EO%G9=RD[T.\[,_$E+6<%)VZ4;E%QUYE3[;US<^S!0"@%
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MXR4]QW#+X5J2X1P-= 8G\,3_ (O-VMK-B-[LOW_VY]A;BX9@VX>1X+:_#HQ
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M]1XC,8?1IU7UN*T*_N'YH\U81LQZ: 4 H!0%1T'S?"* 'I/G/OT!2@% * 4
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M*'8?@/2* C'X"AZ3*N8:?5J^4/Q2>!H"-*5 D$$$=((XB@*4!XG/EJ\] <*
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M?/U'IH5JZ4Z"BEK6-%*) .NA/#7S=%"GH.- * 4 H!0"@% * 4 H!0"@% *
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M&YEIP5NSS,;SK(VK1!NV8Y?CS=P3AV-M)SJZ7=J!C;;B[>VA+Z'G7$J2 V0
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M&[G:+'N_L#;;[OW*N5V3E7AR9O\ $M#3.5V&P69]B1=H-Y]45'FNJ)3&Y&@
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M/?:6E ^S)W**O11^XFS'\T:#][< Y0.;1.IZJYYY-T\Y6F^/BWG_ -,SZ_\
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M ]G;0$?0"@% * 4 H!0%%?(7^(O\DU5<2CX/L,(GI-9AK!2J@4 H!0"@% *
M4 H!0"@% * M;(( 2D364@$K#;X'0HJ.B'=!P!)&AK*LW*OEEP(C<<>,5X\%
M36C]?3^DM>L@B10"@'2=!Q/9U_>H#'&7;H8SB1<C./\ M2ZIX"V6]:%K;5U^
MN2?29B@=AYG/P:RK.)=O:I4AULB,_>\+ K%OQ+WZL?K?!%,1W0QG+"W'0_[*
MNB^'LRX.(0MQ79$D^BQ*\PY5_@TO8EVSJU6/6BF!O>'GM6Z^'??V9/CV/@_\
M:&2/Y?![]8Q,&TNV:2G#+65 @J>N"@"-/1,U[E/W0*A\S\0UT:?0;]L5?Z9"
MO7+]YE^5C$N* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% 5T/PZ]6@Z3YA0&&L
MWWKQ?$R]"MZTY%>T<R?5(3J?4HK@X:3IZ>=L*2>E#?.OJ.E9V-@7K_>?=M]?
M3\AJ^[>:MOV_FLV7XV4NB/LK]J7HZEKV&M,^Y;B;MRBN6^M-H0[Z#2>>%888
M_P"6T-537TCK)<<UZTBI5>ZX"I'6Y3JU?Z#2I7-]\S7>:;:QJZ=%N/8OM-=?
M$R8<4G6J!$0VL3FF(K+2G&4*2L%II*2HLDJ7W9(ZB=*CU>C.3;T;9L[VR]BV
M(1CWU&*3:]"IP(?S\#UCL/97OL,7IH* 4!R0M;:TN-J4AQ!"D+0I2%H4.A25
M)(4DBJ-)JCU15-Q=8MI^@R'8\_E1>2/>$*FL#1(E-A(EMCH],<$2 !^*KRFL
M>YCIZPT?S$SB;Q<M]S)7-'KZ?\S*D"Y0;FR)$"2W(;^=R'Z1LGYKK1 6TKR$
M5B2A*#I)4-@LW[-^'/:DG'_'0>VO)>/%<;;;[M$<@W.''G1'00MB2VEQ!)&@
M4G4<S;B>I22"*]1E*#YH-J1:OV+&3;=K(A&=M]#537K+=CW$%R=A[_>I])9L
MLUP!Q(&IY8,Q6B'/(AW0_A&I*QGKV;R]?Z32]R\J.-;VVNL?_CD]?]LNI=3U
MZC 4R%,MTAR'<(K\*6R='8\EI;+J"#IQ0L E/81P/54G&49KF@TTS3KMNY8N
M.U>BX7%T/B>:JG@4 H!0"@,HX#C4&<PY>+@TB3R251XD=P<S(+24J<><3T.*
MYE@)2> TUTZ*P,J]*+\..C-AV3 LWX/,O)2UI%/AIQ;Z^PS    $@) &@2!H
M  .@ <  !4>]6;3Z%P/?#MLJ:06D<K6NA>7P;'FZUG3J%>7)(OVL>Y=X*BZR
M[85IBP_3Y>^>_P"*X. /X".(3H>LZFK;FV2=K%M6M>,_229.O&O!D\10"@.Q
MKY8_EUB@.R@% * FK?*6XHLN$K]$J0H](T(!!/6./"@):@% * J.@^;X10 ]
M)\Y]^@*4 H"&D_7N><?DB@.B@% * 4 H!0"@% 8SO]G<@ON26D*5$>67$J2.
M#*E'5;;@&O*D*/HGH(K+MR4E3I1!96-*S)R2_AOYBVZ]M4,04 H!0"@% * 4
M H!0"@% * C+S^S)7D#1'D/?-C7[QJY9^\1B9_X2?J^E?I+!K.-=% *#MX&K
MF[VX&11;[.Q:W2O9EOC,QN^=B:HFS#*C-R%AR4"5M,@.\O*CEUT.I-2^%C6G
M!7I*LF:1OVZYD,N6%9DX6(Q56M&VTG\AKWJ3KKQ))42>)*CTJ)/$DU)&J^E\
M0-=01J"""".!!!X$'I'&@_Q_CJ[39[8+(,RRW+;5A#KRKG:YB)(,^:%..VE$
M6,[)Y_7>*WF^1H@-K*E<1RD=%1.Y6[%FS+(2[ZZNDW3RIE;AG[A;VQRY[,ZZ
MRXQ25>/3PI0^KUO@L6R!$M\5/+'AQVX[0/20A(!4K\):M2?*:T^<G*;D^+9W
MVS9A8M1LV_8BJ+_'I/97@NB@% * 4 H!0"@% * 4 H!0"@% * 4 H"Q,QW'Q
M;"&E"[3>^N)3S,V>#R/W%W@>7O&^8(B-$_/=*1IT UDV,6]D/N*D.M\"'W3?
M-OVF/_D3K>II".LG]4>V1J#G&\^59@'84=TV*R+U1[/@.J#\AK7@)\X!#K_,
M.E">1OR&IO'P+-CO/O7.M_4<UW?S1N&Y5M6Y>#B/[,7Q7^J7%^E*B*[98C9[
MTQ,NMT:5*]4F)C,0U*Y8I5W*'RZ^A.BGB2L ))Y>'$&K>?D7+;4(:-JM3*\L
M[3B9MN>5E+F<)T47PX)MOKXFP#:&VD(::0AIIM(0VVVD-MH2. 2A"=$I2.P#
M2HER;=7Q-^48QBHP245P2Z/03C1^C;T_F)_)%46AD]! WJS0I,:3*#?=26F7
M'0XUHGG+:"K1U'R5Z@=/37N$I)T,',Q;-RW*[1*XE6J,9#^7PUE,UU:HK0J*
M 4!ZH<V7;WTR84AV,^G31QI122!\U8^2M'D((KS**FJ21<M7;MF:G:DXR1E&
MR;@M.A$>]M=R[P2F<P-6%>5]D>DT?*C5/DK%N8U-;;)_%WF,FK>4J/\ 67!]
MO49':=:?;0\PZAYEQ(4AQM25H4"-?14DD'X*Q>#H^).1E&<>:#3B^H[.BA4M
M_(<5L.4QO5KU ;D\H(8E(T:FQ2>N/*2.= !X\IU2>L&KEN]<M.L'IU&#F[=A
M[A;\/*@FNOA)=C-:,NV=OEC#LRR*5?;:G51;;;TN<9(.OTD9&HDH2!Q4UQT^
M:*EK.=;N=V?=E\S-%W+RSF8:=[%_C8ZUI]I+LZ3#Y!!*5 I4D\JTJ!2I*ATI
M4D\4D'J-9U4^' UK7@_:7'T/ZO64H!0"A1\&9^VRCORL?[N.VIQ0N$W4C@A/
MU0/.L^BG2HK-:5ZKX4-S\N6KES;U&"J^>7TF9(5B89Y7)1$AWI".(90?Q3Q<
M/GT%1[FZZ<#;K.%"'>N=Y_,3V@    ">@   >8#@*\&:E31<!0"@% * [&_E
M?R[10'90"@% 2-M_6!^:7^50$_0"@% 5'0?-\(H >D^<^_0%* 4!#2?KW/./
MR10'10"@% * 4 H!0"@.+GU3GR/JU_6Z=UT'ZW7_ -/MJJXGFY[#X>O@8AN7
M)ZROD]0UU/-[.]8[C7R=_P"CK^)Z-9D>'Z37[U.;3D_VUI\_U$?52R* 4 H!
M0"@% * 4 H!0"@(R\_LR5^*U^G:JY9^\1B9_X2?8OI18-9QKHH!0H^#-)-X?
M^X5[_-6S_+HU3V%^&B<WW[^ZW.R/[J,95ED.=\;N^_:[WU?DYQS>M>L]QI_S
M?4_ZQR=O+QKS*M-*_-]9<M4\15X>NGKIK0WJ\-O+^_.+\OLGD[NZ\OL7O?4=
M/9,O33O?IN][>?TNVM>W/\+/C6G3VG1?)-/ZS9IR4K+V.'LOKU/HQ_+^6O&M
M9?$[:* 4 H!0"@% * 4 H!0"@% * 4 H!0"@+7R_UOV+)]4_>G7E/>_N?[%]
MM=URGF]7]L^AK^9^FZ>6KUBGB:\G^ZM/F^LP=Q\3W6?A^\<-?!Y/$IZ.?HZZ
M:]1\X+O^U;CI[1_6U_MC]J_*_P#L>;_W7;6U0^ZCP]7L^HX=D_B+GWGM/V_;
M_P!_^KK(ZO1BFPVSW["NO^+#^YLU#;E][']GZSHGD_\  7?YW_:C+E1QMI+Q
M_J4?*Z/G:>YIU54O+@=5P_4)W]CD_H5U5<5VEK)_#S_99AP='W3[YK,9JJX%
M:%10"@% *!\#(V ][WCG=>W/E^GZEZE[(Y?_ -OUOY_XGIUC9%*:\OS_ %$U
MM/-S=WQO5R\O_5]1F"L(V84!R3TCI_V>G[GEJCZ.TJN/3ZC53>+U?VJ]S?N=
MZSJCN_9OM3]Y.3K]I]S_ /$>;O?I-.BIG"KR*GB4]-*>KI.=^9N3WAU]V\2N
MG)S>+_OIW/EUZC"%2)JHJ@/3#[KUICO_ %7NN\3WGKOKGJG+K_[CV?\ UWNN
MWN_2TJDJTTK7T4K\Y[M\OB+FY>7_ %5Y?7R]ZG8;HX=R?N]![K]V^ZT5W?[J
M^L>R>74:<OKG];]8T^L[ST^;IXUK^1]XZ\]?]7'YCK.T4]QCR^!37[FO)Q].
MM?UJ])<U6"1% * 4 H!0'8WU_<^&@.R@% * D;;^L#\TO\J@)^@% * J.@^;
%X10'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g245094tx_pg04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g245094tx_pg04.jpg
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M+W)D9CI21$8^(#PO>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T
M2%!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @   @ " #A"
M24T$)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,     !_]L
MA  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0(! 0(" @$" @,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P  1
M"  ^ L8# 1$  A$! Q$!_\0 R@ !  $% 0$! 0            4! P0&!P@"
M"0H! 0 " P$! 0             $!0$#!@('"!   0,#  8' 0D+"P('
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M+6X8)(9HS5CV'I'2"#H(.D'0=*@RBXO=EHT=):NV[UM7;34K<EHT9"P>P@"
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M<)(*F*9KM@>TM-.T;PJLC4CY<?=Q:3"]PVL >/FDE8!AD$&A!!'000>XH"B
M( @" ( @" ( @" ( @" (#U-Z:?P;C?IK_\ U<GFJC+_ %$O0=[P'^60ZY?B
MD;VHQ<&3%9W4WZN"0C:1N-_&?NM0$C%A)W?K98X^H5D/@ /% 2,6'M(R"\R3
M$4-'G=;HZ"UNDCW4!*-:UH#6@-:T4  H !T #4@*H @" ( @" ( @" ( @"
MC,EJA[7^\U 12 ( @" P7_'=_./OH#Y0!#*VG)<E_N%]_G+C^T<I<?"NHYF_
M^IG]Y^LP5[/ 0$1G_P#8\M_D)_R5LM?F1^\0\_\ 17O]MGGY6QPP0! $ 0!
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M?AD>7*5T'2#T*Y/FA^I'V!P!R!SZ  !_S.ST 4'^PVW0N0\Q_J+?W/\ ,S]
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M_24F1PWB&+^HLW(KGI5=JJN\URH-=.K7U=NQ;2%4( @" ( @" ( @" ( @"
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M4#W;R3R/ROZ=\O6G*_*&*BQ6(M'/DX;7/FN;JYEIQKV_NY2Z>\O)RT;SWG4
M  T #G<C(O95UWK\JS?9Z%R'U[A7".'\$PH\/X9;5O&CR;6V]LI-ZRD^5OT4
M6AMBTED$ 0! $!4:CV?=" '6>T^^@*( @+4DT<0&^=)U-&EQUZ:= T=* Q'7
MWR(_=<?N#S0&.ZZF=]]NC8T;OCK0%@N+M+B2=I)/OH"B ("H)&HD=B P)L9C
M+F43W&.L)YQ2DTUE;2RZ-7Z1\3G&G:O2G-*B;IUFF6/CSEOSMP<^=Q3?J,Q^
MB*1HT-$4@#0*- #'4 :*  +$?$NLVO2-%LH<14PYA[0L@( @" ( @" ( @"
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M+CX:$PF8@UK.XO%>CX(#6:.Q8<V^@D0Q+$.2KZ238QD3=V-C(VC[UC6L'<T
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32 4&T>/D@*@"ATC5U[1U(#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
